Article
SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.
Cancer research - 1 Jun 2017
Ichihara Eiki, Westover David, Meador Catherine B, Yan Yingjun, Bauer Joshua A, Lu Pengcheng, Ye Fei, Kulick Amanda, de Stanchina Elisa, McEwen Robert, Ladanyi Marc, Cross Darren, Pao William, Lovly Christine M
Abstract excerpt
Mutant-selective EGFR tyrosine kinase inhibitors (TKI), such as osimertinib, are active agents for the treatment of EGFR-mutant lung cancer. Specifically, these agents can overcome the effects of the T790M mutation, which mediates resistance to first- and second-generation EGFR TKI, and recent clinical trials have documented their efficacy in patients with EGFR-mutant lung cancer. Despite promising results,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.